Given the established role of the TKT-PKM2 axis in mediating metabolic reprogramming in RCC cells, we further investigated whether blocking this axis could augment the sensitivity of RCC cells to chemotherapy. The gene discussed is TKT; the disease is renal cell carcinoma.